---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-169191"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2024-06-26T23:59:59+00:00"
generated_at: "2026-06-01T01:45:55.892197+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Taysha Gene Therapies prices $75M public offering of common stock and pre-funded warrants

## Summary
- Gross proceeds ~$75M; 14,361,113 shares at $2.25 each and 18,972,221 pre-funded warrants at $2.249 each.
- Net proceeds ~$70M (~$80.6M if underwriters exercise option for 5M additional shares).
- Cash runway extended into Q4 2026; proceeds fund operating expenses and capex.
- Pre-funded warrants exercisable at $0.001 per share with 4.99%/9.99% ownership caps.
- Jefferies, Goldman Sachs, and Cantor act as book-running managers; closing expected June 27, 2024.

## SEC filing metadata
- accession: 0001193125-24-169191
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2024-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312524169191/0001193125-24-169191-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312524169191/d857341d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-169191
- JSON: https://secwatch.observer/filing/0001193125-24-169191.json
- Plain text: https://secwatch.observer/filing/0001193125-24-169191.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.